Biotech firm Windtree Therapeutics plans to buy up to $700 million worth of BNB, the fifth-largest cryptocurrency, to enhance its balance sheet. Following BNB's all-time high price, the company is raising $520 million to fund these purchases after previously announcing a $200 million plan. The firm will collaborate with crypto exchange Kraken for asset custody. Windtree aims to secure additional funds pending stockholder approval, as BNB's market cap is around $106.9 billion with current trading around $769. This move aligns with a growing trend of publicly traded companies diversifying into cryptocurrencies, following examples set by firms like Strategy, Semler Scientific, and others. Windtree's stock has increased by 162% over the past month despite a slight dip following the announcement.

Source šŸ”—